Trials / Completed
CompletedNCT05987696
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML).
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of iPSC NK cells in patients with relapsed/refractory AML or AML Minimal Residual Disease (MRD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD33/CLL1 dual CAR-NK cell | NK cell therapy |
| DRUG | Cyclophosphamid | Lympho-conditioning Agent |
| DRUG | Fludarabine | Lympho-conditioning Agent |
| DRUG | Cytarabine | Lympho-conditioning Agent |
| DRUG | CD33 CAR-NK cell | NK cell therapy |
| DRUG | super NK cell | NK cell therapy |
Timeline
- Start date
- 2023-07-31
- Primary completion
- 2025-01-17
- Completion
- 2025-01-17
- First posted
- 2023-08-14
- Last updated
- 2026-02-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05987696. Inclusion in this directory is not an endorsement.